Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Ipratropium bromide is an anticholinergic medicine sold in respiratory and nasal formulations. This page focuses on the current HFA inhalation aerosol used for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Each actuation contains 17 mcg from the mouthpiece.
read more about ipratropium ...Ipratropium blocks the action of acetylcholine at muscarinic receptors in bronchial smooth muscle. This reduces vagally mediated airway constriction and produces bronchodilation.
Ipratropium HFA inhalation aerosol is used for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. It is not indicated as the first treatment for a sudden bronchospasm episode that requires rapid rescue therapy.
The usual dose is two inhalations four times daily. Additional inhalations can be taken when needed, but the total does not exceed 12 inhalations in 24 hours. The aerosol is used only by oral inhalation.
Serious concerns include hypersensitivity reactions, anaphylaxis, paradoxical bronchospasm, worsening narrow-angle glaucoma, and urinary retention. Use with other anticholinergic medicines can increase anticholinergic adverse effects. Hypersensitivity to ipratropium, atropine derivatives, or product components is a contraindication.
The HFA inhalation aerosol is used for COPD maintenance, including chronic bronchitis and emphysema.
The usual dose is two inhalations four times daily.
Current labeling limits use to 12 inhalations in 24 hours.
No. Current labeling states that it is not the initial treatment for sudden bronchospasm requiring rapid rescue therapy.
ATROVENT HFA (Ipratropium Bromide) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=170e98ef-5560-4068-be7d-e649068eb884. Date Accessed October 5, 2026.
ATROVENT HFA Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021527Orig1s042lbl.pdf. Date Accessed October 5, 2026.
Dose Response to Ipratropium as a Nebulized Solution in Patients With Chronic Obstructive Pulmonary Disease: A Three-Center Study. https://pubmed.ncbi.nlm.nih.gov/2523681/. Date Accessed October 5, 2026.
Ipratropium. https://www.ncbi.nlm.nih.gov/books/NBK544261/. Date Accessed October 5, 2026.
Ipratropium Oral Inhalation: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a695021.html. Date Accessed October 5, 2026.